Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia

Completed · Not applicable

Conditions studied: Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Mast Cell Leukemia, Myeloid/NK-cell Acute Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia

In brief

This clinical trial studies bioelectrical impedance measurement for predicting treatment outcome in patients with newly diagnosed acute leukemia. Diagnostic procedures, such as bioelectrical impedance measurement, may help predict a patient's response to treatment for acute leukemia.

Key facts

Study ID

NCT01869777

Run by

Wake Forest University Health Sciences

People needed

102

Starts

2013-07-01

Expected to finish

2020-05-01

Last updated by the study team

2020-08-13

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hospitalized for newly diagnosed acute leukemia
• Receiving induction treatment while hospitalized
• Willing and able to provide written informed consent

You may not qualify if…

• Presence of a pacemaker or defibrillator
• Patients pregnant at the time of enrollment
• Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients
• Unable/unwilling to follow protocol requirements

Where it is running

• Comprehensive Cancer Center of Wake Forest University — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.